Hypertension is associated with vascular remodeling due to hyperproliferation and hypertrophy of vascular smooth muscle cells (VSMC). Recently, we showed the implication of enhanced expression of Gqa and PLCb1 proteins in hypertrophy of VSMCs from 16-week-old spontaneously hypertensive rats (SHR). The aim of this study was to inves- 
) and results in the activation of protein kinase C (PKC). 3, 4 The Gqa and associated signaling has been shown to contribute to Ang II-induced VSMC hypertrophy. 5 We recently showed that VSMC from 16-week-old spontaneously hypertensive rats (SHR) exhibit enhanced expression of Gqa, PLCb1, and PKCd proteins that contribute to VSMC hypertrophy. [6] [7] [8] Natriuretic peptides (NPs) comprise a family of three peptide hormones; atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP) 9, 10 and regulate a variety of physiological functions including blood pressure through their interaction with natriuretic peptide receptors (NPRs). Three subtypes of NPRs have been identified: NPR-A, 11 NPR-B, 12, 13 .and NPR-C.
14 NPR-A and NPR-B are membrane guanylyl cyclase receptors, whereas NPR-C does not possess guanylyl cyclase activity and is coupled to adenylyl cyclase inhibition through the inhibitory guanine nucleotide regulatory protein Gi, 14, 15 or to activation of phospholipase C (PLC). 16 ANP has been shown to act as an autocrine/paracrine modulator of cardiac hypertrophy and remodelling. [17] [18] [19] We have earlier demonstrated that C-ANP 4-23, an agonist that interacts specifically with NPR-C and small peptide fragments of cytoplasmic domain of NPR-C with Gi activator sequences inhibited vasoactive peptideinduced hypertrophy of A10 VSMC. 20 However, whether C-ANP [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] could also attenuate hypertrophy of VSMC from SHR, a rat model that exhibits cardiac hypertrophy remains obscure. This study therefore investigates the effect of C-ANP 4-23 on the hypertrophy of VSMC from SHR and to explore the implication of different signaling molecules including oxidative stress, c-Src, growth factor receptors, MAP kinase/PI3kinase, and Gqa/PLCb1 proteins in mediating this effect.
| MATERIALS AND METHODS

| Materials
A ring-deleted analog of ANP; C-ANP [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] phenylmethylsulfonyl fluoride, 10 lg/mL aprotinin, 1% Triton X-100, 0.1% sodium dodecyl sulfate, and 0.5 lg/mL leupeptin on ice as described earlier. 23 The cell lysates were centrifuged at 12,000g for 15 minutes at 4°C, and the supernatants were used for Western blot analysis. Cell viability was checked by the trypan blue exclusion technique and indicated that >90%-95% cells were viable. All animal procedures used in this study were approved by the Comite de 
| Western blotting
The levels of protein expression and phosphorylation were determined by Western blotting as described previously. 
| Cell volume measurement
Cell volume measurement was performed as described earlier. 7 VSMCs from 16-week-old SHR and age-matched WKY rats were grown to 50% confluence in cell imaging dish (35 9 10 mm). 
| Determination of superoxide anion production
Basal superoxide anion production in VSMC was measured using the lucigenin-enhanced chemiluminescence method with low concentration (5 lmol/L) of lucigenin as previously described. 
| NADPH oxidase activity determination
The activation of NADPH oxidase activity in the samples was assessed by adding 10 À4 mol/L NADH (Sigma-Aldrich) to the vials before counting. Luminescence induced by basal O 2 -was then subtracted from the luminescence value induced by NADH. 7 
| Statistical analysis
The number of independent experiments is reported. Each experiment was conducted at least 4 times using separate cell population.
All data are expressed as the mean AE SD. Comparisons between groups were made with one way analysis of variance (ANOVA) followed by Dunnett tests using GraphPad Prism5 software. Results
were considered significant at a value of P < .05.
3 | RESULTS
| C-ANP 4-23 attenuates hypertrophy of VSMC from SHR
We earlier showed that C-ANP 4-23 attenuated vasoactive peptideinduced enhanced protein synthesis in A10 VSMC. 20 To investigate ) for 24 hours. The cell lysates were prepared and subjected to Western blotting using specific antibodies against Gqa (A) and PLCb1 (B) as described in "Materials and Methods." Dynein was used as a loading control. The protein bands were quantified by densitometric scanning. The results are expressed as a % of WKY, which is taken as 100%. Values are mean AE SEM of five separate experiments using different cell populations from different animals. *P < .05, ***P < .001 vs WKY CTL, ### P < . ) for 24 hours. The cell lysates were prepared and subjected to Western blotting using specific antibodies against AT1 as described in "Materials and Methods." Dynein was used as a loading control. The proteins were quantified by densitometric scanning as described in ) for 24 hours. The cell lysates were prepared and subjected to Western blotting using specific antibodies against NOX4 (A) and P47phox (B). Dynein was used as the loading control. The proteins were quantified by densitometric scanning as described in "Materials and Methods." Results are expressed as % of WKY CTL, taken as 100%. Values are means AE SEM of 5 separate experiments using different cell populations from different animals. **P < .01 ***P < .001 vs WKY CTL, ## P < .01, ### P < .001 vs SHR CTL attenuation of VSMC hypertrophy is attributed to its ability to inhibit the enhanced activation of ERK1/2 and AKT. To test this, the effect of C-ANP 4-23 treatment on the levels of phosphorylated ERK1/2 (A) and AKT (B) were examined in VSMCs from SHR and WKY rats and the results are shown in Figure 9 . The phosphorylation levels of ERK1/2 and AKT that were enhanced by about 120% and 50%, respectively, in VSMC from SHR as compared to WKY rats were completely abolished by C-ANP 4-23 treatment, however, this treatment, did not affect the phosphorylation of ERK1/2 and AKT in
VSMCs from WKY rats.
| DISCUSSION
We earlier showed that VSMC from 16-week-old SHR exhibit enhanced expression of Gqa and PLCb1 proteins that contribute to VSMC hypertrophy. 6, 7 We also showed that small peptide fragments of the cytoplasmic domain of NPR-C and C-ANP 4-23, an agonist of NPR-C, attenuated the vasoactive peptide-induced hypertrophy of A10 VSMC. 20 However, in this study, we report for the first time The Gqa protein and associated signaling pathway activated by several hormones such as angiotensin II, endothelin, phenylephrine has also been implicated in the development and progression of cardiac hypertrophy and heart failure. [26] [27] [28] [29] [30] In addition, Gqa and the associated signaling pathways, including the activation of IP3-Ca ) for 24 hours. The cell lysates were prepared and subjected to Western blotting using specific antibodies against (phospho)-c-Src (top) and c-Src (bottom) as described in "Materials and Methods." The proteins were quantified by densitometric scanning as described in and ET A receptor antagonists losartan and BQ123 attenuated the enhanced expression of Gqa, PLCb1 as well as increased protein synthesis. 6 In addition, Nakashima et al has also reported the role of Ang II-induced Gq signaling in vascular hypertrophy. 35 In this study,
we show that C-ANP 4-23 attenuated the enhanced expression of AT1 receptor in VSMC from SHR to control levels and suggest that C-ANP 4-23 -evoked antihypertrophic effect may also be attributed to its ability to decrease the levels of AT1 receptor.
Oxidative stress has been shown to play an integral role in the development of cardiovascular disease, including hypertension. 7, 25, 36, 37 The implication of ROS in cardiomyocyte and VSMC hypertrophy has been demonstrated in several studies. [38] [39] [40] We earlier showed the role of enhanced oxidative stress in the overexpression of Gqa and PLCb1 proteins in VSMC from SHR. The role of growth factor receptors in VSMC hypertrophy has been demonstrated by several studies. [42] [43] [44] We earlier showed the implication of growth factor receptor activation in enhanced expression of Gqa and PLCb1 proteins and VSMC hypertrophy in SHR. 22, 36, 45 In this study, we demonstrate for the first time that treatment of VSMC from SHR with C-ANP 4-23 attenuated the enhanced phosphorylation of EGFR, PDGFR, and IGF-1R and suggest that the antihypertrophic effect of C-ANP 4-23 may also be attributed to its ability to attenuate the enhanced activation of growth factor receptors.
We earlier showed the role of c-Src in the increased expression of Gqa and PLCb1 proteins and enhanced protein synthesis in VSMC from SHR. 7 The implication of c-Src in high glucose-induced overexpression of Gqa and PLCb1 in A10 VSMCs has also been reported. 46 Furthermore, c-Src has also been shown as the intervening molecule between oxidative stress and growth factor receptor transactivation because N-acetylcysteine, a scavenger of O 2 À inhibited the enhanced phosphorylation of c-Src, 7 and c-Src inhibitor PP 2 , inhibited the enhanced phosphorylation of PDGFR and IGFR in VSMC from SHR. 7 In this study, we showed that C-ANP 4-23 also attenuated the In conclusion, this study shows for the first time that C-ANP [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] through the activation of NPR-C-attenuates overexpression of AT1 receptor and all the signaling molecules including oxidative stress, c-Src and growth factor receptor activation as well as MAPK/AKT that were shown to be implicated in the enhanced expression of Gqa and PLCb1 proteins in VSMC from SHR and VSMC hypertrophy. 6, 7 Thus, it may be suggested that C-ANP [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] 
